Trilaciclib
Trilaciclib (G1T28) is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively.. Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU chemotherapy[1].
Product Specifications
CAS Number
1374743-00-6
Product Name Alternative
G1T28
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Trilaciclib.html
Purity
99.42
Solubility
DMSO : 6.73 mg/mL (ultrasonic; warming; adjust pH to 5 with 1 M HCl; heat to 60°C)
Smiles
O=C1NCC2(N3C1=CC4=CN=C(NC5=NC=C(N6CCN(C)CC6)C=C5)N=C43)CCCCC2
Molecular Formula
C24H30N8O
Molecular Weight
446.55
Precautions
H302, H315, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
(1-acetyl-2,3-dihydro-1H-indol-5-yl)boronic Acid
